Metastatic Merkel Cell Carcinoma: Insights on the Clinical Application of Immune Checkpoint Inhibitors

In this downloadable slideset, distinguished faculty members Paul Nghiem, MD; Shailender Bhatia; MD, Sandra P. D’Angelo, MD; and Evan J. Lipson, MD, review key data and current practice changes in the treatment of advanced MCC. For additional in-depth analysis of the slideset, please review the accompanying CME-certified text module.
Format: Microsoft PowerPoint (.ppt)
File Size: 8.41 MB
Released: February 22, 2017

Acknowledgements

This activity is supported by an educational grant from
Pfizer Inc.
Merck KGaA

Related Content

In this slideset from Clinical Care Options (CCO), experts provide insights on the optimal use of CAR T-cell therapy for lymphomas

person default Caron A. Jacobson, MD Released: June 16, 2021

In this slideset from Clinical Care Options (CCO), experts provide insights on CAR T-cell strategies for myeloma

Noopur Raje, MD Released: June 16, 2021

In this slideset from Clinical Care Options (CCO), experts provide insights on the optimal use of CAR T-cell therapy for ALL

Jae H. Park, MD Released: June 16, 2021

From Clinical Care Options (CCO), video featuring expert insights on the integration of CAR T-cell therapy into community care

person default Caron A. Jacobson, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: June 14, 2021 Expired: June 13, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue